news

Experimental treatment for Niemann-Pick disease appears safe

An experimental drug has appeared to slow the progression of Niemann-Pick disease type C1…

Niemann

An experimental drug has appeared to slow the progression of Niemann-Pick disease type C1 (NPC1), the drug, 2-hydroxypropyl-beta-cyclodextrin (VTS-270), is being tested under a cooperative research and development agreement (CRADA) between the National Institute of Health (NIH) and Sucampo Pharmaceuticals, Inc.

The study was a phase 1/2a clinical trial designed to test the drug’s safety and effectiveness. A group of 14 participants, ranging from ages 4 to 23 years, received the experimental drug once a month at NIH for 12 to 18 months.

Another group of three participants received the drug every 2 weeks for 18 months at Rush University Medical Centre in Chicago. Initially, participants were divided into groups receiving different doses of the drug, but after observing that the drug was safe and well-tolerated by those receiving the highest doses, the researchers increased dosing for all participants. Their progress was compared to a previous group of 21 NPC1 participants enrolled in an earlier study that documented disease progression. 

The researchers did not observe any serious adverse outcomes related to the drug. However, the participants, most of whom had already experienced hearing loss because of the disease, had additional hearing loss after treatment. Earlier studies had shown that the treatment carries the risk for hearing loss. In the current study, hearing loss was compensated with hearing aids, which enabled participants to go about their daily lives.

Because NPC1 symptoms result from cholesterol build-up in brain cells, the researchers also measured cholesterol metabolism in the participants’ central nervous system. They found that after treatment, a molecule derived from cholesterol metabolism in neurons, 24(S)-hydroxycholesterol, had increased. In addition, most participants had lower levels of two proteins indicative of brain injury, FABP3 and calbindin D, implying that there was less damage in the brain. According to the study authors, these results suggest that VTS-270 can improve cholesterol metabolism in neurons, thereby targeting the root of the problem.

The researchers also evaluated the drug’s effectiveness using a neurological severity score, where higher scores indicate more severe effects from the disease. Compared to an earlier group of patients who had not received the drug, VTS-270-treated participants had lower scores in measures of cognition and speech, with mobility scores also trending lower. The authors believe these differences indicate that treatment with the drug can stabilise or slow disease progression.

“The results are very encouraging and support continued development of VTS-270 for treating NPC1,” said Dr Forbes D. Porter, clinical director at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the study’s senior author. “Compared to untreated patients we followed in an earlier study, participants who received VTS-270 scored better on a scale used to evaluate disease severity and progression, including elements such as speech, cognition and mobility.”

NICHD researchers led the design, data collection and analysis of the phase 1/2a clinical trial. VTS-270 was provided by Janssen Research & Development, a Johnson & Johnson company. Researchers are now working on a randomised, controlled phase 2b/3 clinical trial (NCT02534844) that has been approved by the U.S Food and Drugs Administration (FDA) and the European Medicines Agency (EMA). The trial results will help determine which symptoms are most responsive to the drug and provide information for refining the dose and dosing frequency.

The goal of this trial is to obtain regulatory approval of VTS-270. 

Send this to a friend